Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife’s strategy to reach the company’s full potential and thereby create increased shareholder value.Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and

Fabege sells residential development rights in Huvudsta to JM

Fabege sells development rights to JM. The development rights are located in Huvudsta in Solna and consist of four residential projects.The development rights have been granted legal approval and the local development plan allows for an above ground development right of almost 42,500 sqm, which corresponds to around 450 homes and a preschool. The buyer also takes on an obligation to pay the remaining amount to the City of Solna an infrastructure development contribution. The sale will take place through a share transfer and the handover date is 4 April 2023. The real estate worth of the

Exel Composites awarded with first prize in the small cap category of the Best Investor Pages -competition

EXEL COMPOSITES PLC      INVESTOR NEWS      1 FEBRUARY 2023 at 9:00 EETExel Composites was awarded the first prize in the small cap category of the Best Investor Pages -competition. Best Investor Pages is an annual competition arranged by the Finnish Foundation for Share Promotion and the Finnish Society of Financial Analysts that aims to improve the investor communications of companies listed on the Nasdaq Helsinki.   This year, the competition looked at the usability and visual appearance of the websites, and how the company communicates to investors in the following areas: strategy,

JM moves its head office to Fabege and Haga Norra

Fabege and JM have signed a lease agreement for 6,526 sqm in the office project Kvarter 1, property Ackordet 1. The lease is for 6 years, with an annual rent of almost SEK 25m excluding supplements. JM is expected to move in during the third quarter of 2024.Haga Norra is the next major development district in Arenastaden, an area that provides as much inspiration and as many experiences outside the office as inside. The construction of Kvarter 1 began in 2021 and it covers 27,000 sqm. Fabege’s total investment in the project is estimated at approximately SEK 1.4bn. The property is in the

Dividend amount in XACT Nordic High Dividend Low Volatility (UCITS ETF)

The dividend amount of the above stated Exchange Traded Fund is SEK 6.68 per fund unit. SEK 1.67 will be distributed in March, May, September and in November. Registered holder of fund units on the record day will receive dividend. The schedule for the dividend is as follows: Dividend 1 – SEK 1.67March 14                  Last day to trade fund units including the right to receive dividendMarch 15                  Ex-dividend; the fund units are traded ex dividendMarch 16                  Record dayMarch 21                  Payment day Dividend 2 – SEK 1.67 May 8

Invitation to presentation of Balder’s year-end report 2022

On 10 February at 08:00 (CET), Fastighets AB Balder will be publishing its year-end report for January to December 2022. The year-end report will be published at balder.se . On the same day, at 08:45, Balder’s CEO Erik Selin and CFO Ewa Wassberg will be holding an online presentation and telephone conference that analysts, investors, the media and other stakeholders are welcome to attend. The presentation will be held in English, and during the telephone conference there will be an opportunity for representatives from the

Block Listing Application

("Amaroq" or the "Company") Block Listing Application TORONTO, ONTARIO - February 01, 2023 - Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ - formerly AEX Gold), an independent mine development company with a substantial land package of gold and strategic mineral assets covering an area of 7,866.85 km[2] in Southern Greenland, has made an application to the London Stock Exchange for a block listing of securities in respect of 1,330,000 common shares (the "New Common Shares") to be admitted to trading on AIM, with admission expected to become effective on or around 06

ABGSC to publish Q4 2022 Interim Report on 8 February

ABG Sundal Collier (“ABGSC”) will publish its Q4 2022 figures on 8 February 2022 at 08.00 CET. The report will be available on our corporate website www.abgsc.com. Webcast presentation CEO Jonas Ström will present the Q4 result through a webcast at 09.00 CET followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information: Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts: Anna Tropp, Head of Communications, +46 722 30 94 17

Dividend amount in XACT Sverige (UCITS ETF)

The dividend amount of the above stated Exchange Traded Fund is SEK 20.54 per fund unit. Registered holder of fund units on the record day will receive dividend.   The schedule for the dividend is as follows: June 12         Last day to trade fund units including the right to receive dividend June 13         Ex-dividend; the fund units are traded ex dividend June 14         Record day June 20         Payment day The above applies unless otherwise published. For further information, please contact:         Stefan Hagman, Handelsbanken Fonder AB:  +46 70 – 611 18 68

Getinge Year End Report 2022:“External challenges remain but are expected to ease in 2023”

“The order intake and net sales declined organically by 6.7% and 5.3% during the quarter, mainly as a result of continuing external challenges,” says Mattias Perjos, President & CEO of Getinge. “Hospitals have not yet recovered to pre-pandemic levels for elective surgery, are generally experiencing lower productivity than before the pandemic, and have low treatment needs related to seasonal influenza”.Getinge reports challenging comparative figures in products for COVID-19 treatment and vaccine production and the challenges in the supply chain continue, which negatively impacted net sales

JM acquires building rights for residential development in Solna, Stockholm, and signs agreement for new head office

JM has acquired building rights from Fabege for the development of approximately 450 residential units located in Huvudsta, Solna. The property value in the acquisition amounts to SEK 484m, including a paid development contribution. Occupancy and payment will take place during the second quarter of 2023.The acquired building rights are included in the detailed plan for Huvudsta 3:1 in Solna Municipality just north of Stockholm. The detailed plan has gained legal force and allows for the development of approximately 450 residential units. The acquisition will be reported within the JM

JM Year-end Report January–December 2022

Strong result in a weak marketRevenue increased to SEK 16,385m (14,608). Operating profit decreased to SEK 2,064m (2,216). The operating margin decreased to 12.6 percent (15.2). Gains/losses from sale of properties and from joint venture of SEK −11m (436) are included in the operating profit. Profit before tax decreased to SEK 1,994m (2,158), and profit after tax decreased to SEK 1,575m (1,798). Return on equity for the past twelve months amounted to 17.9 percent (21.9). Earnings per share during the year amounted to SEK 23.40 (25.90). Consolidated cash flow including net

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 1, 2023, at 9.00 am EETRepurchase of Outokumpu’s own shares On January 31, 2023, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |87 |5.196

TIE Kinetix Reports Q1 2023 Trading Update

TIE Kinetix, a leader in 100% supply chain digitalization, announces its trading update for the first quarter of financial year 2023 today.High Growth Plan on track with Q1, 2023 Record Order Intake  TIE Kinetix today reports that the High Growth Plan is on track for 2023 with a record high Q1, 2023 order intake of € 6.1 million (Q1, 2022: € 2.8 million). Investments in sales and marketing are paying off with an all-time high order intake. From this € 6.1 million order intake, 72% was related to SaaS, compared to 52% in Q1, 2022. SaaS revenues have grown by 18% in the first quarter to

Invitation to Q4 Earnings Teleconference

Karnov Group (Nasdaq: KAR) will publish its financial report for the fourth quarter and the financial year 2022 on 15 February at around 08.00 a.m. CET and Management will host a webcasted telephone conference the same day at 09.00 a.m. CET.Karnov Group’s year-end report for the period January – December 2022 will be published on Wednesday 15 February 2023 at around 8.00 a.m. CET. A webcasted telephone conference will be held at 09.00 a.m. CET the same day, where CEO Pontus Bodelsson and Interim CFO Leif Mårtensson will present the report and answer questions.   You can follow the

Neste to publish its 2022 results on 8 February 2023

Neste Corporation, Press Release, 1 February 2023 at 9 a.m. (EET) Neste will publish its fourth quarter and full-year 2022 results on Wednesday, 8 February 2023 at approximately 9 a.m. (EET). The release will be available on the Neste website  immediately after publishing. A conference call in English for investors and analysts will be held on Wednesday, 8 February 2023, at 3 p.m. Finland / 1 p.m. London / 8 a.m. New York. In order to receive the participant dial in numbers and a unique personal PIN, participants are requested to register using this link:

Proposals of the Shareholders’ Nomination Committee to Kesko’s 2023 Annual General Meeting

The Shareholders’ Nomination Committee of Kesko Corporation submits the following proposals to the Annual General Meeting planned to be held on 30 March 2023. The proposals will also be included in the Notice of General Meeting, to be published later. Board members' fees The Shareholders' Nomination Committee proposes that the remuneration of Board members and the reimbursement of their expenses remain unchanged. The proposal regarding the remuneration of Board members and the reimbursement of their expenses in 2023-2024 is as follows: · Board Chair, an annual fee of €102,000 ·

News conference on Kojamo’s Financial Statements Release 2022 on 15 February 2023

Kojamo plc Press Release, 1 February 2023 at 9:00 a.m. EETNews conference on Kojamo’s Financial Statements Release 2022 on 15 February 2023 Kojamo plc’s Financial Statements Release 2022 will be published on Wednesday, 15 February 2023 at approximately 8:00 a.m. EET. Kojamo will publish Financial Statements and the Report of the Board of Directors as well as Corporate Governance Statement and Remuneration Report 2022 on the same day. News conference webcast Kojamo will hold a news conference for institutional investors, analysts and media on 15 February 2023 at 10:00 a.m. EET as a

Erant docendi expetendis in pri, sed an saperet platonem  - EN - Corrected 2

Lorem ipsum dolor sit amet, ridens consulatu vim eu, quidam dissentiet his eu, usu id modus salutatus. Id est ullum epicuri salutatus, in probo quaeque gloriatur pri. Duo modus causae ad. Ne reque dolor nam, sit eu suas imperdiet omittantur.   His postea pertinax definiebas ne, eu illum nonumy euismod sed. Error accommodare pri an, malorum iudicabit laboramus sit ei. Duis accusata eos te. Possim lobortis pri at, ei soleat urbanitas cum. Dico inermis epicuri ei cum, stet ignota qui no. Nobis latine ocurreret ius te. Qui ex sint dicam mediocrem, cetero feugiat ei has. Quo utinam

Raisio plc: The cancellation of Raisio plc’s treasury shares entered in the Trade Register

Raisio plc  Stock Exchange Release, 1 February 2023   The cancellation of Raisio plc’s treasury shares entered in the Trade Register   Based on the resolution on forfeiture made by Raisio plc’s Annual General Meeting on 12 April, 2022, the 587,728 of series K shares and 178,270 series V shares on the Joint Account were transferred to the company. On 19 January, 2023 Raisio plc announced the decision of its Board of Directors to cancel the said shares.   The cancellation of the treasury shares has today been registered with the Trade Register maintained by the Finnish

Lagercrantz Interim Report 1 April - 31 December 2022

THIRD QUARTER (1 OCTOBER – 31 DECEMBER 2022)•    Net revenue increased by 38% to MSEK 1,941 (1,405), of which organic growth amounted to 10%. •    Operating profit (EBITA) increased by 43% to MSEK 323 (226), equivalent to an EBITA margin of 16.6% (16.1).•    Cash flow from operating activities amounted to MSEK 439 (172).•    Profit after financial items (EBT) increased by 31% to MSEK 251 (191).•    Profit after taxes increased by 34% to MSEK 199 (148).  NINE MONTHS (1 APRIL – 31 DECEMBER 2022)•    Net revenue increased by 33% to MSEK 5,206 (3,907), of which organic growth

Arctic Bioscience – First patient included in HRO350 Phase IIb clinical trial in the UK

Reference is being made to the stock exchange release from January 12[th] 2023 where Arctic Bioscience announced that the Clinical Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate psoriasis with the investigational medicinal product (IMP) HRO350 was approved in the United Kingdom (UK).Arctic Bioscience has met a key milestone in the drug development program for HRO350. The first patient has been included in the clinical trial “A phase IIb, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in patients with

Elkem expands production capacity for carbon solutions in Brazil

Elkem has decided to invest around NOK 200 million to increase its production capacity in Brazil for pitch, a raw material for electrode paste to industrial smelters.The investment is based on well-known technology and constitutes an expansion of a running Elkem facility, thereby further improving productivity and profitability. The increased production of high-quality products will be supplied to a major customer on a long-term contract. Elkem will also have options to sell additional supply to others. The investment will increase the production capacity by up to 40 per cent from 2024, and

YEAR-END REPORT JANUARY - DECEMBER 2022

Strong growth in the fourth quarterFourth quarter 2022 · Net sales increased by 26% to SEK 10,353m (8,234). Organic sales growth was 8%, changes in exchange rates contributed with 14% and acquisitions with 4%. · Operating income was SEK -1,737m (-132) and the operating margin -16.8% (-1.6). Excluding items affecting comparability, operating income was SEK -13m (-180) and the operating margin -0.1% (-2.2). · Items affecting comparability amounted to SEK -1,724m (48) and was mainly related to the acceleration of the strategic transformation announced in October 2022, see pages 9

There are no items matching the current filter
There are no more items matching the current filter
Back to top